Duke CRISPR Tool Restores Prostate Tumor Visibility, Boosting Immunotherapy in Mice
Updated
Updated · SciTechDaily · Jul 24
Duke CRISPR Tool Restores Prostate Tumor Visibility, Boosting Immunotherapy in Mice
2 articles · Updated · SciTechDaily · Jul 24
Summary
A Duke-led preclinical study used an RNA-targeting CRISPR-Cas13 tool to keep SPSB1 mRNA at its normal length, making prostate tumors visible again to the immune system and sharply improving checkpoint therapy in mice.
The treatment blocks cancer cells from shortening SPSB1 mRNA—a change that otherwise raises SPSB1 protein, strips away MHC-I from the cell surface and leaves "immune-cold" tumors hard for T cells to detect.
Restoring the longer mRNA reduced SPSB1, brought MHC-I back to tumor cells and drew more immune cells into the tumors, addressing a key reason immunotherapy has largely failed in most prostate cancers.
Researchers reported no off-target effects in their analysis, but the approach remains preclinical and still needs further testing to establish safety and effectiveness in people.
The Nature Biomedical Engineering study suggests abnormal mRNA shortening may help multiple cancers evade treatment, raising the prospect of combining this strategy with existing immunotherapies beyond prostate cancer.